2023年第63届澳大利亚风湿病协会年度科学会议（ARA）将于2023年5月5日至9日澳大利亚霍巴特举行，澳大利亚风湿病协会（ARA）成立于1984年，是澳大利亚风湿病界的最高专业协会。它是皇家澳大利亚医学院的专业学会，其成员参与各种形式关节炎的治疗和研究，包括自身免疫性结缔组织病，脊柱和软组织疾病，骨疾病（例如骨质疏松症）和慢性肌肉骨骼疼痛综合征。 ARA支持和教育成员和其他从业人员在肌肉骨骼领域，给患者提供最佳的护理。通过培训，专业发展，研究和宣传，促进卓越的诊断和肌肉骨骼和炎症性疾病的管理。 ARA年度科学会议是有关这些病症的管理和研究的各个方面的澳大利亚主要会议，不仅风湿病学专家，而且涉及该领域的相关组织以及澳大利亚强大的风湿病科学界的成员都聚集在一起。

Invited Speakers

Professor Janet Pope (Canada)

MD MPH FRCPC 

Dr. Janet Pope is a Professor of Medicine and member of the Division of Rheumatology at the University of Western Ontario (UWO), Schulich School of Medicine, London, Ontario, Canada.  Her research includes studies in scleroderma, SLE and RA.  She has published over 500 peer-reviewed articles. She has received the Distinguished Investigator Award from the Canadian Rheumatology Association, Rheumatologist of the Year from the Ontario Rheumatology Association, Department of Medicine Research Achievement Award, and the Dean’s Award of Excellence in Research. She has been inducted into the Canadian Academy of Health Sciences, the highest achievement for a health care professional in Canada.

A/Professor Edward Vital (UK)

MB ChB, MRCP (UK), PhD

NIHR Leeds Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust

Leeds Institute of Rheumatic and Musculoskeletal Medicine

University of Leeds, Leeds, United Kingdom

Ed Vital is an Associate Professor in Autoimmune Connective Tissue Diseases and Honorary Consultant Rheumatologist, at Leeds Teaching Hospitals NHS Trust in the UK. He is the Head of the Leeds Lupus Research Group with interests in early disease, skin disease, musculoskeletal outcome measures, translational immunology, and B cell therapies.

Dr Vital studied Medicine and Surgery at the University of Manchester and became a Member of the Royal College of Physicians in 2004. In 2012, he completed his PhD, at the University of Leeds studying B cell depletion therapy.

He is a Member of the SLEuro executive committee, chair of the British Society for Rheumatology Special Interest Group for SLE, and Chair of the British Isles Lupus Activity Group, a member of the global steering committee of Transform Lupus and Chair of the Lupus Forum. In 2018 he won a the Medical Research Foundation Emerging Leaders Award, and in 2019, he won the British Society for Rheumatology Michael Mason Prize. 

His research covers a broad range of clinical translational themes. In early SLE he has characteristed an “At Risk” population and shown that development of SLE can be predicted by Type I interferon status. From this finding, his group then showed that from the earliest phases of pre-clinical disease, Type I interferon production does not come from plasmacytoid dendritic cells as once thought, but from non-haematopoietic cells in target organs such as the skin, reversing the concepts of some conventional models of autoimmunity. In established disease he has extensively investigated the efficacy and mechanism of action of B cell depletion, demonstrating the importance and mechanism of depth of depletion, and the existence of B cell independent-inflammation in cutaneous disease. In lupus arthritis he used imaging to develop new outcome measures, trial designs and treatment strategies. Key current interests include stratification of early and established disease and interferon biomarkers, in which he is leading an international TaskForce.

Clinical A/Professor Andrea Low (Singapore)

Clinical Associate Professor at Duke-National University of Singapore and Head of Department, Rheumatology and Immunology, Singapore General Hospital (Singhealth)

Dr Andrea Low is Clinical Associate Professor at Duke-National University of Singapore and Head of Department, Rheumatology and Immunology, Singapore General Hospital (Singhealth). Her clinical and research interest is in systemic sclerosis (SSc). She spear-headed the nation-wide collaborative SSc research workgroup dedicated to advancing clinical care and research in SSc, and established the Systemic Sclerosis Cohort in Singapore (SCORE) cohort since 2008. She is recipient of the Clinician Scientist Award for her work in SSc. She is convenor of the Asia Pacific League of Associations of Rheumatology (APLAR) SSc special interest group and member of the Scleroderma Clinical Trials Consortium, contributing to the education sub-committee. She led her Department to recognition as the APLAR Centre of Excellence (since 2017). In partnership with Jansenn, their multi-disciplinary Cardiology, Respiratory and Rheumatology pulmonary hypertension team at Singhealth is recognised as a Centre of Excellence for Pulmonary Hypertension that serves as a regional reference centre for training and management of all causes of pulmonary hypertension.

Professor Athimalaipet V. Ramanan (UK)

FRCPCH, FRCP 

Athimalaipet V. Ramanan is a consultant pediatric rheumatologist at the Bristol Royal Hospital for Children. He is the joint lead for research (Division of Women and Children) at the Bristol Royal Hospital for Children, and Professor of Paediatric Rheumatology at the University of Bristol. 

Professor Ramanan is a medical advisor for  Olivia’s Vision. He is also Co-Chair for the National Institute for Health Research Clinical Research Network: Children/Arthritis Research UK (ARUK) Paediatric Rheumatology Clinical Studies Group, and Associate Director for the UK Experimental Arthritis Treatment Centre for Children (JIA-Uveitis and Industry work streams). He was awarded the British Society of Rheumatology’s Innovation in Clinical Practice Award in 2010.  He was also awarded the University of Bristol Vice Chancellor’s Health Impact award in 2017 and Royal College of Physicians/NIHR CRN Award for outstanding contribution to research in 2018. 

Professor Ramanan’s has published >225 articles and numerous book chapters covering a variety of topics in the field of rheumatology. He is the Co-Editor of Rheumatology and Associate Editor for the Archives of Diseases in Childhood.

He is one of the Editors of 5th Edition of Oxford Textbook of Rheumatology.

He has also led trials of Tocilizumab and Baricitinib in COVID-19 and part of the paediatric steering committee of the RECOVERY trial.

Mr Will Gregory (UK)

Consultant Physiotherapist and Clinical Governance Lead

Rheumatology Directorate, Salford Royal Hospital, Salford Care Organisation 

Part of the Northern Care Alliance NHS Group

Will is a Consultant Physiotherapist, employed by the Rheumatology team at the Salford Care Organisation, part of the Northern Care Alliance NHS Foundation Trust in Greater Manchester, UK. He is also an Honorary Senior Lecturer at Manchester Metropolitan University teaching on the Advanced Practice and First Contact Practitioner MSc modules on the early detection and assessment of rheumatological conditions. He is also part of the team delivering the MSc in Rheumatology at Keele University. He completed a BSc with honours in Physiotherapy in 2001 at the University of Manchester, UK and an MSc in Physiotherapy in 2013 at the Manchester Metropolitan University, UK.

Will is a published author in the rehabilitation of Myositis, of Scleroderma, of Fibromyalgia and of Axial Spondyloarthritis. His Scleroderma rehab research was an RCT where he acted as PI under an Honorary Research Associate contract at the University of Manchester. He has been a topic expert on guideline developments in Myositis with the British Society for Rheumatology(BSR) and Rheumatoid Arthritis with the National Institute for Health and Care Excellence.

Will has led on a UK-wide survey of rheumatology physiotherapy practice and on the subsequent development of the Chartered Society of Physiotherapy and BSR-endorsed “Rheumatology Physiotherapy Capabilities Framework”. He has a passion for advancing AHP roles in Rheumatology and striving for equity of access to rheumatology physiotherapy services across the UK. He has recently published in delay to diagnosis in Axial Spondyloarthritis and sits on a national task force group to decrease delay across the UK.

Will co-chairs the recently formed national Rheumatology Physiotherapy Clinical Interest Group (CIG) in the UK. With more than 20 years NHS physiotherapy experience, he runs Injection, Pain and Axial Spondyloarthritis clinics at Salford and also has a role as Clinical Governance Lead for the Rheumatology team. He is active on social media as @PhysioWillGreg and as a part of the national CIG @RheumPT_MACP

常规注册包括：会议、展览、会议资料、茶歇等

随行人员注册包括：茶歇、进入展区参观

早鸟注册:须于早期注册截止前完成注册及汇款，如汇款晚于截止日期前到达，则不能享受早鸟价

其它：会议接待、预订展位、境外研修、考察培训、海外推广、机票酒店预定、翻译、境外接送机、会后旅行等请联系我们

参会流程：点击立即报名或联系客服，提交需求客服联系参会人沟通->>确定代办业务并签订合同->>付款->>操作代办业务->>顺利出行

支付方式：线上支付（请联系客服）线下支付请前往银行柜台支付您的参会费用

汇款账号及注意事项

单位名称：领域国际商务服务（北京）有限公司

银行名称：招行北京青年路支行

银行账号：110923888910803

注意事项：转账汇款时，请务必确认收款信息是否正确，并填写备注说明，确保填写完整参会，参会人姓名+会议简称+款项用途（例：姓名+DDW+注册费）如果您的汇款信息不完整，会导致无法识别该笔汇款出处。如果您进行银行转账，请务必提供银行汇款单作为证明，以便追踪款项，请将汇款单发送至lingyumed@126.com,一旦确认汇款，注册将在24小时内被确认。

如果汇款后3个工作日内未与您确认订单收款，请及时与我们联系！

联系电话：010-57571855

会议报名咨询：010-57571855 18911270084